Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer

Abstract

Trastuzumab improves overall survival for women with HER2-positive breast cancer but is associated with cardiotoxicity, especially when administered after anthracyclines. Use of non-anthracycline trastuzumab-based regimens is rising, particularly for patients with low-risk disease or with multiple cardiovascular risk factors. We performed a single-center… (More)
DOI: 10.1007/s10549-017-4362-x

3 Figures and Tables

Topics

  • Presentations referencing similar topics